Osur and colleagues’ article on the evaluation findings of implementing misoprostol for post- abortion care (PAC) in Kenya and Uganda provides valuable lessons learned and best practices. Venture Strategies Innovations (VSI), a global health non-profit organization, is currently introducing misoprostol for PAC with the Ministries of Health (MOH) in Rwanda and Zimbabwe, and based on our ongoing implementation experiences, we would suggest a few additional lessons.
The Angola Ministry of Health, in collaboration with VSI, conducted a demonstration project aimed at addressing maternal deaths due to complications from unsafe abortion. This research brief demonstrates that misoprostol is a safe, effective and feasible treatment method for incomplete abortion at all levels of the health system, including those facilities that do not have the capacity for manual vacuum aspiration or other surgical interventions.
Information, education and communication (IEC) campaign sample from a postpartum hemorrhage (PPH) operations research project in Rwanda using the local Kinyarwanda language.
VSI’s Global Misoprostol Map presents a snapshot of the current registration status of misoprostol worldwide. Registration is the process by which a drug is approved by a regulatory agency for importation, distribution and marketing for a specific medical indication after a thorough review of its effectiveness, safety and manufacturing process. It is a key strategy and critical first step to improving access to any drug or device.
